PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 17):
An antibody that specifically binds to human LILRB2, wherein the antibody comprises the following six complementarity determining regions (CDRs):\n (a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15; (b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17; (d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18; (e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19; and (f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.742396797785841
- 35 USC 102 Novelty (BERT): 0.5355384593928721
- Combined Prediction Score: 0.7217109639465442
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 286.3027147127437

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test